stock here: a substacker implicates him as the top fiend in the COVID murders. I uncovered one of the pieces. he took over Roche and then bought the rights to the PCR test. That is immediately suspicious.
This is also important
https://www.bioworld.com/articles/485384
Roche purchased the PCR technology from Cetus Corp. for $300 million in 1991, when the latter merged with Chiron Corp., of Emeryville, Calif.
The above article was from May 11, 2020, exactly 2 months after the WHO declared the “Pandemic” on evil date 3-11-2020. He died from a stroke just days before, he got to live to see the roll out of the pandemic and his PCR machines being used as the justification atrocities
Fritz Gerber (22 March 1929 – 10 May 2020) was a prominent Swiss business executive and philanthropist, renowned for his leadership roles in two major Swiss corporations: Zurich Insurance Group and Hoffmann-La Roche (Roche).
Early Life and Education
Born in Huttwil, Switzerland, Gerber pursued legal studies at the University of Bern, earning a law degree and subsequently being admitted to the bar. His academic background laid a strong foundation for his future roles in corporate leadership.
Career at Zurich Insurance Group
In 1958, Gerber began his career with Zurich Insurance. Demonstrating exceptional aptitude, he quickly ascended the corporate ladder, becoming General Manager in 1969 and Chief Executive Officer (CEO) in 1974. He held the CEO position until 1991 and served as Chairman of the Board from 1977 to 1995. Under his stewardship, Zurich Insurance evolved into a leading global insurance provider.
Leadership at Hoffmann-La Roche
Simultaneously, Gerber took on the role of CEO at Roche in 1978, a position he maintained until 1998, while also serving as Chairman until 2001. His tenure at Roche was transformative; he guided the company through significant expansions, notably:
Biotechnology Advancements: Gerber orchestrated the acquisition of a majority stake in Genentech in 1990, positioning Roche at the forefront of biotechnology and leading to the development of groundbreaking cancer therapies.
Diagnostic Innovations: Under his leadership, Roche acquired polymerase chain reaction (PCR) technology in 1991 and purchased Boehringer Mannheim in 1997 for $11 billion, establishing Roche as a global leader in molecular and laboratory diagnostics.Philanthropic Endeavors
Beyond his corporate achievements, Gerber was deeply committed to supporting young talent. In 1999, he established the Fritz Gerber Foundation for Gifted Young People, which provides financial assistance to young individuals excelling in fields such as arts, crafts, and sports within Switzerland.
Legacy
Fritz Gerber’s visionary leadership not only propelled Zurich Insurance and Roche to new heights but also left an indelible mark on the global business landscape. His strategic foresight and commitment to innovation continue to influence these industries today. Gerber passed away on 10 May 2020, at the age of 91, following a stroke.——————————————————————-
Fritz Gerber, who led Roche as CEO from 1978 to 1998 and as Chairman until 2001, passed away in May 2020. His strategic decisions, particularly the acquisition of Genentech and the integration of PCR technology, positioned Roche as a leader in biotechnology and diagnostics. These foundational moves have been instrumental in Roche’s ability to respond effectively to health crises, including the COVID-19 pandemic.
Reuters
While mRNA vaccines have been pivotal in combating COVID-19, Roche’s primary contributions during the pandemic have centered on diagnostics and therapeutic collaborations. Notably, Roche partnered with Regeneron to develop and manufacture casirivimab and imdevimab, a monoclonal antibody cocktail authorized for emergency use in treating COVID-19.
Wikipedia
In summary, Fritz Gerber’s visionary leadership laid the groundwork for Roche’s advancements in biotechnology and diagnostics. Although he was not directly involved in the development of COVID-19 treatments or mRNA vaccines, his legacy has undeniably influenced Roche’s capacity to address such global health challenges.